Bexmarilimab granted key US patent
Faron Pharmaceuticals Oy (“Faron” or the “Company”) Bexmarilimab granted key US patent Company announcement, 14 June 2021 at 9.00 AM (EEST) TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the United States Patent and Trademark Office has granted a new US Patent, No. 11,046,761, with claims protecting the composition of matter of bexmarilimab. The patent will be issued on 29 June, 2021. Faron's wholly-owned novel precision cancer immunotherapy drug candidate, bexmarilimab,